Replies to post #401276 on Anavex Life Sciences Corp (AVXL)

[WolfofMia]

Safe to ignore this nonsense also.

Nothing like being told to be an investor lol.

Like WTF have we been doing for 7 years?

[falconer66a]

Just the science, only.

Ignore the pumping and bashing, folks. There's a lot of it out there

Well, sure; along with the Fear, Uncertainty, and Doubt (FUD) stuff.

I'll stick with the science. It's been certain and positive in every case. No one has ever posted a paper or scientific report showing that the Anavex molecules fail to favorably activate the sigma-1 receptor. There have been no science nor real-biology failures for blarcamesine in either murines (lab rodents) or humans. It will just take some time (and final clinical results) for the "market" (both retail and institutional stock investors) to understand the truth. I can wait. In the meantime, I'm entertained by the FUD posts, such as the one that prompted this response.

[Mikesc]

I see you went long!

[Gator328]

Almost. There is another outcome: Anavex fails the trial, and pursues an over-the-counter route, and in a few years becomes the next Herbalife. Cristiano Ronaldo will wear Anavex on his soccer jersey just like David Beckham promoted Herbalife when he played for the LA Galaxy. Anavex becomes a household name, and nobody cares that the FDA rejected it. It's not like half the country isn't suspicious of Dr. Fauci and the FDA and would see rejection as a badge of honor. Blarcamesine would be available in every CVS, Walgreens, Kroger, and Amazon. Or the company could go the MLM route instead...

Honestly, getting approval just seems easier. I'm fairly certain that's the path of least resistance, assuming all continues to go well with the FDA trials. I am thankful that Dr. Missling is smart and experienced enough to ignore the message board arm chair quarterbacks. There are plenty of instances where criticism is warranted. I just don't see it here, if delays are the biggest shareholder gripe. That seems more like a shareholder's problem to me.